DeepMed Research

Vanda Pharmaceuticals

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 203

Market Cap: $311.8M

Website

Introduction: Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Clinical Trials

Motion Delos: An Open Label Safety and Efficacy of Tradipitant in Participants Affected by Motion Sickness

Phase 3

Recruiting

Conditions: Motion Sickness

Interventions: Drug: Tradipitant

First Posted Date: 2023-11-18

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 500

Registration Number: NCT06138613

Locations: 🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States

Motion Serifos: A Study to Investigate the Efficacy of Tradipitant in Participants Affected by Motion Sickness

Phase 3

Completed

Conditions: Motion Sickness

Interventions: Drug: Tradipitant
Drug: Placebo

First Posted Date: 2023-06-15

Last Posted Date: 2025-04-04

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 316

Registration Number: NCT05903924

Locations: 🇺🇸
Pacific Research Partners, San Diego, California, United States
🇺🇸
Lumos Clinical Research, San Jose, California, United States
🇺🇸
Santa Monica Clinical Trials, Santa Monica, California, United States

and more 2 locations

Safety and Tolerability of Open-Labeled Iloperidone in Adolescents

Phase 4

Recruiting

Conditions: Schizophrenia
Bipolar I Disorder

Interventions: Drug: Iloperidone

First Posted Date: 2022-12-13

Last Posted Date: 2025-03-04

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05648591

Locations: 🇺🇸
Vanda Investigational Site, Everett, Washington, United States

Bioequivalence Study Between Tasimelteon Capsule Formulation and Liquid Suspension Formulation in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Tasimelteon Oral Capsule
Drug: Tasimelteon Oral Suspension

First Posted Date: 2022-10-07

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 36

Registration Number: NCT05572281

Locations: 🇺🇸
Vanda Investigational Site, Springfield, Missouri, United States

Evaluating the Effects of Tasimelteon in Individuals With Autism Spectrum Disorder (ASD) and Sleep Disturbances

Phase 3

Recruiting

Conditions: Autism Spectrum Disorder
Sleep Disorder
Neurological Disorder
Sleep Disturbance

Interventions: Drug: Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension

First Posted Date: 2022-05-05

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 100

Registration Number: NCT05361707

Locations: 🇺🇸
Vanda Investigational Site, Staten Island, New York, United States

A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis

Phase 2

Withdrawn

Conditions: Parkinson Disease Psychosis

Interventions: Drug: Iloperidone

First Posted Date: 2022-04-25

Last Posted Date: 2024-03-21

Lead Sponsor: Vanda Pharmaceuticals

Registration Number: NCT05344365

Locations: 🇺🇸
Vanda Investigational Site, Saint Petersburg, Florida, United States

Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: VHX-896 and iloperidone
Drug: Iloperidone and VHX-896

First Posted Date: 2021-07-20

Last Posted Date: 2022-07-11

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 25

Registration Number: NCT04969211

Locations: 🇺🇸
Vanda Investigational Site, Springfield, Missouri, United States

Effects of Tradipitant on Satiation, Gastric Volume, Gastric Accommodation, and Gastric Emptying in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: Placebo
Drug: Tradipitant

First Posted Date: 2021-04-19

Last Posted Date: 2024-04-16

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 27

Registration Number: NCT04849559

Locations: 🇺🇸
Vanda Investigational Site, Rochester, Minnesota, United States

Evaluation of Efficacy and Safety of Iloperidone in the Acute Treatment of Manic or Mixed Episodes Associated With Bipolar I Disorder

Phase 3

Completed

Conditions: Bipolar I Disorder

Interventions: Drug: Iloperidone Placebo
Drug: Iloperidone

First Posted Date: 2021-03-29

Last Posted Date: 2024-04-18

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 417

Registration Number: NCT04819776

Locations: 🇵🇱
Vanda Investigational Site, Tuszyn, Poland

Evaluating the Effects of VQW-765 vs. Placebo in Performance Anxiety

Phase 2

Completed

Conditions: Performance Anxiety

Interventions: Drug: Placebo
Drug: VQW-765

First Posted Date: 2021-03-16

Last Posted Date: 2024-03-20

Lead Sponsor: Vanda Pharmaceuticals

Target Recruit Count: 230

Registration Number: NCT04800237

Locations: 🇺🇸
Vanda Investigational Site, Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy